Allos Pharma Inc., a US-based biopharmaceutical company specialising in the development of treatments for rare neurological disorders, announced on Monday that it has expanded its intellectual property rights for Arbaclofen with a new patent family that was filed to the United States Patent Trademark & Office earlier in 2023.

This new patent family is in addition to the company's present granted patent family.

The company also has worldwide exclusive rights to granted patents and clinical programs for arbaclofen in further indications, which includes autism spectrum disorder. This is in addition to the present Fragile X Syndrome development program, for which there are no approved medications, and where the product has Orphan Drug Designation.

Dr Randall Carpenter, MD, co-founder of Allos Pharma Inc, said: "This license builds upon the progress in our Fragile X Syndrome program, where we have achieved alignment with the fragile X community and the FDA on the design of the confirmatory Phase 3 clinical trial. We are excited to have the rights to develop arbaclofen in additional indications as clear efficacy signals were observed in recent trials in individuals with idiopathic Autism Spectrum Disorder."